Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q4 FY22 Earnings Presentation
19 slides from Eris Lifesciences's earnings presentation, May 3, 2022
Slide 1: Eris Lifesciences Limited – Investor Presentation filing letter
EY Entrepreneur of the year-2013 2013 FROST & SULLIVAN Hest Practices-2013 Business today/YES dank Excellence Awards-2033 Eris Eris Lifesciences Limited Date: 3rd May, 2022 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla C
Slide 2: Q4 FY22 and FY22 Investor Presentation
Q4 FY 22 and FY 22 INVESTOR PRESENTATION 3rd May 2022 1
Slide 3: Financial Highlights – Q4 FY22 and FY22
FINANCIAL HIGHLIGHTS – Q4 FY 22 and FY 22 Q4 FY 22 FY 22 INR mn INR mn INR mn INR mn 3,059 969 13,470 4,850 10.0% 2.5% 11.2% 12.6% Op Revenue yoy growth EBITDA yoy growth Op Revenue yoy growth EBITDA yoy growth INR mn INR mn 800 4,058 17.2% 14.3% PAT yoy growth PAT yoy growth • Q4 FY 22 has been a v
Slide 4: Business Highlights – FY22
BUSINESS HIGHLIGHTS – FY 22 78 % 20 % 33.9 % 33.4 % OCF to Dividend ROIC * ROE * EBITDA Payout Ratio • INR 378 crore Operating Cash Flow in FY 22; continue to be among the highest in the industry • Guwahati operations accounted for 79% of revenue in FY22 • New manufacturing facility announced in Q1
Slide 5: Eris Has Grown at 3x the Market Rate from Pre-Covid Levels
ERIS HAS GROWN AT 3x THE MARKET RATE FROM PRE-COVID LEVELS 12.6% Eris has outperformed the IPM by 620 bps since pre-Covid times 9.8% 9.2% 9.2% 8.0% 7.9% 6.8% 6.5% 6.3% 5.0% 3.0% IPM exl. Covid IPCA TORRENT ERIS LS INTAS SUN* MANKIND USV CADILA EMCURE* MACLEODS Molecules % Acute Therapy contribution1
Slide 6: Sustained Outperformance in Core Therapies from Pre-Covid Levels
SUSTAINED OUTPERFORMANCE IN CORE THERAPIES FROM PRE-COVID LEVELS ORAL ANTI-DIABETES : 32% of Eris CARDIOLOGY : 28% of Eris VMN: 19% of Eris 7.2% over IPM 11.8% 3.8% over IPM 10.9% 4.4% over IPM 9.9% 7.1% 5.5% 4.6% IPM ERIS IPM ERIS IPM ERIS CNS: 8% of Eris WOMEN’S HEALTH: 4% of Eris • Eris has grown
Slide 7: Continued Outperformance vs IPM Despite Slowdown in Cardio-Metabolic Market
CONTINUED OUTPERFORMANCE vs IPM DESPITE A SIGNIFICANT SLOWDOWN IN OUR CORE CARDIO-METABOLIC MARKET Eris grew at 9.2% in Q4 FY 22 vs. IPM growth of 3.9%; outperformed IPM in Cardio-Metabolic, CNS & Women’s Health therapies IPM Eris Cardio-Metabolic : 60% of Eris VMN : 19% of Eris 21.6 18.5 15.5 15.9
Slide 8: Eris Maintains High Prescription Ranking Among Doctor Specialties
ERIS MAINTAINS HIGH PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 3 4 4 DIABETOLOGISTS CARDIOLOGISTS NEUROLOGISTS 5 CONSULTING 6 GASTROENTEROLOGISTS PHYSICIANS Source: SMSRC MAT Feb 2022 * Rank in Represented Market 7
Slide 9: Recent Key Launches to Propel Growth Momentum in FY23 and Beyond
RECENT KEY LAUNCHES TO PROPEL GROWTH MOMENTUM IN FY 23 AND BEYOND 8
Slide 10: Power Brands Leading Presence in Core Therapies (1/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/2) Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea rank 6 in the ≈4,800 cr Glimepiride and combinations market Glimisave MV rank 6 in Glimepiri
Slide 11: Power Brands Leading Presence in Core Therapies (2/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/2) High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ≈3,700 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipin
Slide 12: Jan 2022 – Leveraged the Insulin/GLP1 Opportunity with MJ Biopharm
JAN 2022 - LEVERAGED THE INSULIN/ GLP1 OPPORTUNITY WITH MJ BIOPHARM • Leading position in Indian oral anti-diabetes • Proven capabilities in developing advanced biological formulations from preclinical • Strong credibility with Diabetologists/ through to Phase III and regulatory approval Endocrinolo
Slide 13: Eris Continues to Execute on Growth Drivers (1/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (1/2) Expansion of power- • Our business model of building strong and sustainable brands has enabled us to significantly 1 brands’ franchise outperform the market • There has been a clear shift in prescriber preference towards established brands over the l
Slide 14: Eris Continues to Execute on Growth Drivers (2/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (2/2) Expansion of physician • We continue to make good progress in expanding our coverage of Specialists and 3 coverage Consulting Physicians in line with our expectations • We are expanding our field-force by ~ 170 (120 Reps and 50 Managers) Therapeutic
Slide 15: Q4 FY22 and FY22 – Standalone Income Statement
Q4 FY 22 AND FY22 - STANDALONE INCOME STATEMENT Standalone Q4 FY 22 FY 22 INR Millions Q4 FY 22 Q4 FY 21 FY 22 FY 21 yoy Gr % yoy Gr % Sale of Products 2,771 2,527 9.7% 11,938 10,886 9.7% • Operating Revenue grew by 9.8% yoy in Q4 FY 22 and by Other Operating Income 50 42 20.3% 220 202 8.8% 9.6% yoy
Slide 16: Q4 FY22 and FY22 – Consolidated Income Statement
Q4 FY 22 AND FY22 - CONSOLIDATED INCOME STATEMENT Consolidated Q4 FY 22 FY 22 Q4 FY 22 Q4 FY 21 FY 22 FY 21 INR Millions yoy Gr % yoy Gr % Branded Formulation Sales Sale of Products 3,011 2,743 9.8% 13,262 11,926 11.2% Q4 FY 22 FY 22 Other Operating Income 48 40 22.6% 209 192 8.6% INR Millions Q4 FY
Slide 17: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Name of Shareholder 31-Mar-22 31-Dec-21 30-Sep-21 Others FPIs 0.38% 689* 760* 761* 13.31% Promoters 52.66% 52.66% 52.68% 1 UTI Mutual Fund 5.53% 5.44% 5.18% 2 ChrysCapital (Emerald Investment Limited)
Slide 18: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 19: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 18